Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 115

1.

The consequences and costs of chronic kidney disease before ESRD.

Hunsicker LG.

J Am Soc Nephrol. 2004 May;15(5):1363-4. Review. No abstract available.

PMID:
15100382
[PubMed - indexed for MEDLINE]
Free Article
2.

Managed care is not the "cure-all" for improving quality and controlling costs in ESRD.

Amerling R.

Nephrol News Issues. 1999 Apr;13(4):46-7. No abstract available.

PMID:
10418448
[PubMed - indexed for MEDLINE]
3.

The organization and financing of kidney dialysis and transplant care in the United States of America.

Hirth RA.

Int J Health Care Finance Econ. 2007 Dec;7(4):301-18.

PMID:
17602296
[PubMed - indexed for MEDLINE]
4.

Costs and consequences of ESRD in NC.

Norman M, Young H, Bell RA.

N C Med J. 1997 May-Jun;58(3):165. No abstract available.

PMID:
9164124
[PubMed - indexed for MEDLINE]
5.

Drugs take the spotlight in steering clinical, economic direction for ESRD.

Neumann ME.

Nephrol News Issues. 2004 Jun;18(7):50-1. No abstract available.

PMID:
15232997
[PubMed - indexed for MEDLINE]
6.

Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy.

Alexander CM, Lyle PA, Keane WF, Carides GW, Zhang Z, Shahinfar S.

Kidney Int Suppl. 2004 Nov;(92):S115-7. Review.

PMID:
15485403
[PubMed - indexed for MEDLINE]
Free Article
7.

Chronic kidney disease and medicare.

St Peter WL.

J Manag Care Pharm. 2007 Dec;13(9 Suppl D):S13-8. Review.

PMID:
18177214
[PubMed - indexed for MEDLINE]
Free Article
8.

Health care reform: focus on prevention would help decrease costs associated with ESRD.

Kaufer S.

Nephrol News Issues. 1994 Jul;8(7):10-1. No abstract available.

PMID:
8047172
[PubMed - indexed for MEDLINE]
9.

Disease management improves ESRD outcomes.

Sands JJ.

Int J Artif Organs. 2006 Feb;29(2):154-9.

PMID:
16552663
[PubMed - indexed for MEDLINE]
10.

Employer-paid nonmedical costs for patients with diabetes and end-stage renal disease.

Kamal-Bahl SJ, Pantely S, Pyenson B, Alexander CM.

Prev Chronic Dis. 2006 Jul;3(3):A83. Epub 2006 Jun 15.

PMID:
16776884
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

ESRD as a window into America's cost crisis in health care.

Knauf F, Aronson PS.

J Am Soc Nephrol. 2009 Oct;20(10):2093-7. doi: 10.1681/ASN.2009070715. Epub 2009 Sep 3. No abstract available.

PMID:
19729435
[PubMed - indexed for MEDLINE]
Free Article
12.

The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathy.

Carides GW, Shahinfar S, Dasbach EJ, Keane WF, Gerth WC, Alexander CM, Herman WH, Brenner BM; RENAAL Investigators.

Pharmacoeconomics. 2006;24(6):549-58.

PMID:
16761903
[PubMed - indexed for MEDLINE]
13.

The economic burden of end-stage renal disease in Canada.

Zelmer JL.

Kidney Int. 2007 Nov;72(9):1122-9. Epub 2007 Aug 15.

PMID:
17700643
[PubMed - indexed for MEDLINE]
14.

Introduction: chronic kidney disease: a burgeoning health epidemic.

St Peter WL.

J Manag Care Pharm. 2007 Dec;13(9 Suppl D):S2-5. Review.

PMID:
18177212
[PubMed - indexed for MEDLINE]
Free Article
15.

Telemedicine project looks to improve ESRD care, lower costs. TRC/Georgetown University Medical Center begin two-year experiment.

Neumann ME.

Nephrol News Issues. 1997 Oct;11(10):67-9. No abstract available.

PMID:
9391397
[PubMed - indexed for MEDLINE]
16.

Chronic renal failure in India.

Mani MK.

Natl Med J India. 1994 Mar-Apr;7(2):80-4. No abstract available.

PMID:
8019405
[PubMed - indexed for MEDLINE]
17.

Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective.

Burgess ED, Carides GW, Gerth WC, Marentette MA, Chabot I; Canadian Hypertension Society.

Can J Cardiol. 2004 May 1;20(6):613-8.

PMID:
15152291
[PubMed - indexed for MEDLINE]
18.

A patient-directed fee-for-service system can work for ESRD.

Amerling R.

Nephrol News Issues. 2002 Sep;16(10):25-6. No abstract available.

PMID:
12271926
[PubMed - indexed for MEDLINE]
19.

Clinical and economic outcomes of Staphylococcus aureus septicemia in ESRD patients receiving hemodialysis.

Nissenson AR, Dylan ML, Griffiths RI, Yu HT, Dean BB, Danese MD, Dubois RW.

Am J Kidney Dis. 2005 Aug;46(2):301-8.

PMID:
16112049
[PubMed - indexed for MEDLINE]
20.

Chronic kidney disease: the distribution of health care dollars.

St Peter WL, Khan SS, Ebben JP, Pereira BJ, Collins AJ.

Kidney Int. 2004 Jul;66(1):313-21.

PMID:
15200439
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk